Coeptis Therapeutics Inc.

Quarterly Report for period ending 2022-06-30

Quarterly Report for period ending 2022-03-31

Annual Report for period ending 2021-12-31

Quarterly Report for period ending 2021-09-30

Quarterly Report for period ending 2021-06-30

Quarterly Report for period ending 2021-03-31

Quarterly Report for period ending 2021-03-31

Transition report pursuant to Rule 13a-10 or 15d-10 for period ending 2020-12-31

Quarterly Report for period ending 2020-11-30

Quarterly Report for period ending 2020-08-31

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Reflects information that constitutes a substantive change from or addition to the information set forth in the last offering circular

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

Reflects information previously omitted from the offering circular in reliance on Rule 253(b)

None

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

Exempt (Private) Offering

Exempt (Private) Offering

Hutchinson Thomas: Major Shareholders

Mehalick David: Statement of changes in beneficial ownership of securities

Mehalick David: Initial statement of beneficial ownership of securities

Lena Pharma, LLC: Major Shareholders

Yerace Daniel Alexander: Initial statement of beneficial ownership of securities

Lisa Pharma, LLC: Major Shareholders

Sheehy Christine Elise: Initial statement of beneficial ownership of securities

Registration Withdrawal Request

General form of registration statement for all companies including face-amount certificate companies

General form of registration statement for all companies including face-amount certificate companies

Offering statement under Regulation A

Definitive proxy statement relating to a merger, acquisition, or disposition

Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

Preliminary proxy statement relating to a merger, acquisition, or disposition

Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.